Common diabetes treatment may cause bladder cancer

NewsGuard 100/100 Score

A commonly used diabetes treatment may increase patients' risk for bladder cancer, show US study findings.

"The results from this study suggest that 5 or more years of exposure to thiazolidinediones (TZDs) may be associated with a higher incidence of bladder cancer than comparable exposure to SUs [sulfonylureas]," say Ronac Mamtani (University of Pennsylvania, Philadelphia) and colleagues.

The US Food and Drug Administration recently warned that use of pioglitazone may be associated with an increased risk for bladder cancer. The warning, however, was based on limited data from the Kaiser Permanente Northern California (KPNC) diabetes registry, the French national health information system, and the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study, say the researchers.

"None of the previous studies directly compared the TZDs with the sulfonylureas (SUs), the common alternative therapy for Type 2 diabetes not adequately controlled with metformin," explain Mamtani et al.

Using The Health Improvement Network database, the team conducted a retrospective study of 59,855 patients with Type 2 diabetes who received a prescription for either a TZD or SU between July 2000 and August 2010.

As reported in the Journal of the National Cancer Institute, there were 197 incident bladder cancers diagnosed over 196,708 person-years of follow up, with incident rates of 87.1 and 107.2 per 100,000 person-years with TZD and SU use, respectively.

The team reports that there was no significant difference in risk for bladder cancer between TZD and SU users.

However, the risk was increased with longer time since initiation of TZD therapy. Those who initiated TZD therapy 5 years or more previously were at more than three times the risk for bladder cancer than those who had started treatment less than 1 year earlier.

The team also found that the increase in risk over time with TZD therapy was significantly greater for TZD use than with SU use. Those who initiated TZD therapy more than 5 years previously were more than twice as likely to develop bladder cancer than those who initiated SU therapy at the same time point.

"The reproducibility of the findings from the US and French studies, and now using UK data, provides support for the hypothesis that long-term treatment with the TZDs may be associated with an increased risk of bladder cancer relative to the common alternative therapy, an effect that does not seem unique to pioglitazone," warn Mamtani and team.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Common diabetes treatment may cause bladder cancer. News-Medical. Retrieved on May 27, 2024 from

  • MLA

    Robertson, Sally. "Common diabetes treatment may cause bladder cancer". News-Medical. 27 May 2024. <>.

  • Chicago

    Robertson, Sally. "Common diabetes treatment may cause bladder cancer". News-Medical. (accessed May 27, 2024).

  • Harvard

    Robertson, Sally. 2018. Common diabetes treatment may cause bladder cancer. News-Medical, viewed 27 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cancer researchers urged to embrace AI for groundbreaking insights and efficiency